Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $26.04, for a total value of $309,381.24. Following the completion of the sale, the chief operating officer directly owned 377,802 shares in the company, valued at approximately $9,837,964.08. This represents a 3.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
- On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
- On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
- On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total transaction of $304,272.41.
- On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.50, for a total transaction of $302,965.50.
- On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total transaction of $304,866.46.
- On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total transaction of $346,806.39.
- On Friday, October 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.13, for a total transaction of $334,212.53.
Adaptive Biotechnologies Stock Up 3.0%
ADPT stock traded up $0.76 during trading on Monday, hitting $26.27. 1,164,225 shares of the stock traded hands, compared to its average volume of 2,124,122. Adaptive Biotechnologies Corporation has a one year low of $12.00 and a one year high of $30.74. The company has a 50 day simple moving average of $26.17 and a 200 day simple moving average of $19.42. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. On average, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its position in shares of Adaptive Biotechnologies by 1.3% during the second quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock worth $684,000 after purchasing an additional 416 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Adaptive Biotechnologies by 6.8% during the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares during the last quarter. Gibbs Wealth Management increased its holdings in shares of Adaptive Biotechnologies by 4.6% in the third quarter. Gibbs Wealth Management now owns 26,900 shares of the company’s stock valued at $777,000 after purchasing an additional 1,191 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after purchasing an additional 1,401 shares in the last quarter. Finally, Nykredit A S bought a new position in Adaptive Biotechnologies in the 2nd quarter worth approximately $31,000. Institutional investors own 99.17% of the company’s stock.
Analyst Ratings Changes
Several brokerages have recently commented on ADPT. Piper Sandler boosted their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Guggenheim raised their price target on Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, October 1st. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a report on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. Finally, BTIG Research lifted their price objective on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $30.06.
View Our Latest Stock Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.
Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Featured Stories
- Five stocks we like better than Adaptive Biotechnologies
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
